Forte Biosciences (NASDAQ: FBRX) will be bought for $77 cash per share in a tender offer from argenx BV, representing a premium to the current $76.44 price. The deal gives shareholders immediate liquidity and positions the company under a larger biotech parent, potentially enhancing resources and valuation.

Key Highlights

  • Tender offer price set at $77.00 per Share, payable in cash.
  • The stock price shows a substantial gain in recent trading
  • Short interest represents 15% of outstanding shares, covering 1.7 days of volume.
  • Board unanimously recommends acceptance, aiming to make the company a wholly owned subsidiary of argenx.

Forte Biosciences announced a cash tender offer of $77.00 per share, converting the company into a wholly owned subsidiary of argenx BV. With a market capitalization of roughly $1.1 billion, the deal translates the firm’s equity into immediate cash for shareholders while preserving its pipeline under a larger biotech umbrella. The board’s unanimous endorsement underscores confidence that the transaction will maximize shareholder value.

Cash Offer Triggers Acquisition

The tender proposal stipulates a fixed cash outlay of $77.00 for each outstanding share, with no interest attached. Investors may tender their holdings within a minimum 15‑business‑day window that begins shortly after the offer’s launch, which is slated to commence within ten business days of the agreement. The offer price is subject to standard adjustments for withholding taxes but otherwise remains firm.

Because the consideration is cash, holders receive immediate liquidity without the need to sell on the open market, effectively locking in the premium. This structure also eliminates the uncertainty of future dilution that might accompany a stock‑based deal.

Merger Mechanics and Shareholder Obligations

The transaction follows a two‑step process: first, the tender offer seeks to secure more than 50% of the outstanding shares plus one additional share, satisfying the minimum condition for closure. Once that threshold is met, the acquiring entity, Avena Merger Sub Inc. a wholly owned subsidiary of argenx, will merge with the company under Delaware law, leaving the surviving corporation as a subsidiary of the parent. All outstanding options and restricted stock units convert to cash based on the $77.00 per‑share figure, with unexercised options priced below the offer receiving a lump‑sum payout.

Unvested options priced at or above the offer are cancelled without compensation. The agreement also imposes a “no‑shop” clause, limiting the company’s ability to entertain competing proposals unless a superior offer is identified. This narrow gap suggests investors anticipate a high likelihood of deal completion.

Short interest sits at 15 % of the float, translating to 1.7 days of average volume to cover, a modest figure that reflects limited resistance to the transaction. Peer biotech names posted modest gains, SRPT up 3.6 %, ZYME up 1.5 %, ANAB up 0.4 %, indicating sector‑wide optimism but not eclipsing Forte’s outsized move. The premium and cash nature of the deal provide a clear upside for holders while removing downside linked to future clinical outcomes.

Upcoming Milestones and Risks

The tender period is expected to close in mid-August, with the earliest possible merger consummation shortly thereafter, subject to antitrust clearance and customary closing conditions. Investors should monitor the expiration of the offer window and any regulatory filings that could affect the timeline. Failure to meet the minimum share threshold or a breach of the agreement’s covenants could delay or derail the merger, potentially reopening the short‑interest dynamic.

The next decisive event is the tender offer’s expiry, which will confirm whether the cash premium is fully realized.

Peers Moving on This News

  • Sarepta Therapeutics Inc (SRPT) up 3.6%
  • Zymeworks Inc (ZYME) up 1.5%
  • AnaptysBio Inc (ANAB) up 0.4%

Analysis based on the Form 8-K filed 27 July 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.